secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001104659-24-132481
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M
--------------------------------------------------------------------------------

- Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
- Authorized common shares reduced from 200,000,000 to 16,666,667; par value unchanged.
- No fractional shares issued; cash payment will be made in lieu of fractional shares.
- Proportionate adjustments made to stock options, equity plan reserves, and exercise prices.
- Stockholder-approved at June 4, 2024 annual meeting; board approved specific ratio Dec 19, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924132481/0001104659-24-132481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924132481/tm2430195d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-132481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer